Regulatory PathRegulatory requirements compared

Active substances

Latanoprost + Timolol

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
LATANOCOM OPHTHALMIC SOLUTION5,0.05 mg/ml,mg/mlOphthalmic solution · Ophthalmic use1 Dropper ContainerSAR 33.40Generic · PrescriptionJamjoom Pharmaceuticals Factory CompanyValid
Ocuotan Plus0.05,5 mg/ml,mg/mlEye drops, solution · Ocular use1 Dropper ContainerSAR 30.05Generic · PrescriptionAdvanced Pharmaceutical IndustriesValid
XALACOM EYE DROP5,0.05 mg/ml,mg/mlEye drops, solution · Ophthalmic use1 Dropper ContainerSAR 33.40NCE · PrescriptionViatris HealthcareValid
Indications — CHI Daman Drug Formulary

OPEN ANGLE GLUCOMA

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
JAMP-LATANOPROST/TIMOLOL0245377050 MCG / ML; 5 MG / MLSOLUTION · OPHTHALMICJAMP PHARMA CORPORATION
LATANOPROST / TIMOLOL0255384850 MCG / ML; 5 MG / MLSOLUTION · OPHTHALMICJAMP PHARMA CORPORATION
M-LATANOPROST-TIMOLOL025145165 MG / ML; 50 MCG / MLSOLUTION · OPHTHALMICMANTRA PHARMA INC
MED-LATANOPROST-TIMOLOL0245450550 MCG / ML; 5 MG / MLSOLUTION · OPHTHALMICGENERIC MEDICAL PARTNERS INC
MYLAN-LATANOPROST/TIMOLOL023730685 MG / ML; 50 MCG / MLSOLUTION · OPHTHALMICMYLAN PHARMACEUTICALS ULC
TEVA-LATANOPROST-TIMOLOL024362565 MG / ML; 50 MCG / MLSOLUTION · OPHTHALMICTEVA CANADA LIMITED
XALACOM0224661950 MCG / ML; 5 MG / MLSOLUTION · OPHTHALMICBGP PHARMA ULC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
NHS Drug TariffLatanoprost 50micrograms/ml / Timolol 5mg/ml eye drops£3.442.5 ml1 Oct 2026
NHS Drug TariffLatanoprost 50micrograms/ml / Timolol 5mg/ml eye drops 0.2ml unit dose preservative free£13.4930 unit dose1 Oct 2026
NHS Drug TariffLatanoprost 50micrograms/ml / Timolol 5mg/ml eye drops preservative free£13.492.5 ml1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.